Candoxatril, A Neutral Endopeptidase Inhibitor - Efficacy and Tolerability in Essential-Hypertension

Objective:To examine the efficacy and tolerability of the neutral endopeptidase inhibitor, candoxatril (UK 79,300) as monotherapy in essential hypertension.Design:Double-blind, placebo-controlled, parallel-group study of 28 days' duration.Setting:Three hospital outpatient departments participating i